Gilead Sciences, Inc.

Arcus Biosciences, Inc.

Other

Rhiannon Thomas-Tran

Jay Patrick Powers

Manmohan Reddy Leleti

Dillon Harding Miles

Joel Worley Beatty

Jenna Leigh Jeffrey

James G Taylor

Jeromy J Cottell

Zheng-Yu Yang

Nathan E Wright

Chienhung Chou

Brandon Reid Rosen

Debashis Mandal

Ehesan Ul Sharif

Chao-I Hung

Chandrasekar Venkataramani

Peter A Blomgren

Gediminas J Brizgys

Elbert Chin

Musong Kim

Zhimin Du

James S Cassidy

Kavoos Kolahdouzan

Michael T Tudesco

Laurent Debien

William John Watkins

Michael L Mitchell

Sheila M Zipfel

Scott D Schroeder

Xuelei Yan

Suet Chung Yeung

Julian Andrew Codelli

Kenneth Victor Lawson

Nathan D Shapiro

Stephen E Ammann

Gayatri Balan

Gregg M Schwarzwalder

Helen Yu

Samuel Lawrie Drew

Suzanne M Szewczyk

Daniel G Shore

Chen Chen

Dorothée Saddier Axe

Brian M Weist

Michael Graupe

David W Lin

Erick Allen Lindsey

Laurent Pierre Paul Debien

Guillaume Mata

Anh Thu Tran

Artur Karenovich Mailyan

Steven Donald Jacob

Jeremy Thomas Andre Fournier

Rebecca Louise Grange

Jeremy Fournier

Ezra Roberts

Ehesan Ui Sharif

Megan K Armstrong

Compounds that inhibit PI3Kγ, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by PI3Kγ.

2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds

The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.

IKAROS Zinc Finger Family degraders and uses thereof

Compound that is an inhibitor of at least one of the Aand Aadenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine Areceptor and/or the adenosine Areceptor.

Azolopyrimidine for the treatment of cancer-related disorders

The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition.

GLP-1R modulating compounds

The present disclosure relates to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2, including cancer.

IKAROS zinc finger family degraders and uses thereof

The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

Compounds, such as compounds having Formula (I): wherein each variable is as described herein, that modulate the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5′-nucleotidase, ecto is also provided.

CD73 inhibitors

Compounds of Formula I that inhibit at least one of the Aand Aadenosine receptors, and compositions containing compounds of Formula I and methods for synthesizing compounds of Formula I, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine Areceptor and/or the adenosine Areceptor.

Quinazoline-pyridine derivatives for the treatment of cancer-related disorders

Growing community of inventors

San Jose, CA, United States of America

Rhiannon Thomas-Tran